July 27, 2015.
Teva Pharmaceutical Industries Ltd. (Petach Tikva, Israel) has announced that it has signed a definitive agreement to acquire the generics business of Allergan (Dublin, Ireland) in a transaction valued at $40.5 billion. Upon closing, Allergan will receive $33.75 billion in cash and shares of Teva valued today at $6.75 billion. The Israeli firm simultaneously announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary shares of Mylan N.V. (Amsterdam, The Netherlands). http://www.tevapharm.com/news_media/
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.